Hui Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hui Zhang has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Yong-Ming Yao
Medical Innovation Research Division and Fourth Medical Center of the Chinese PLA General Hospital
2 shared publications - Yong-Wen Feng
Department of Critical Care Medicine, Shenzhen Guangming District People’s Hospital, Shenzhen, China
1 shared publication
Latest Publications
- Open Access
- 25 July 2019
- Published by Elsevier in Military Medical Research
- Vol. 6 (1) , 1-3
Better therapy for combat injury
- 25 July 2019
- Published by Elsevier in Military Medical Research
- Vol. 6 (1) , 1-3
Open AccessBetter therapy for combat injury
- Open Access
- 26 November 2018
- Published by Springer Nature in Military Medical Research
- Vol. 5 (1) , 1-11
Potential therapy strategy: targeting mitochondrial dysfunction in sepsis
Recently, the definition of sepsis was concluded to be a life-threatening organ dysfunction caused by a dysregulated host response to infection. Severe patients always present with uncorrectable hypotension or hyperlactacidemia, which is defined as septic shock. The new definition emphasizes dysregulation of the host response and multiple organ dysfunction, which is partially attributed to metabolic disorders induced by energy crisis and oxidative stress. Mitochondria are a cellular organelle that are well known as the center of energy production, and mitochondrial damage or dysfunction is commonly induced in septic settings and is a predominant factor leading to a worse prognosis. In the present review, we determine the major mitochondrial disorders from morphology to functions in sepsis. In the following, several clinical or pre-clinical assays for monitoring mitochondrial function are demonstrated according to accumulated evidence, which is the first step of specific therapy targeting to modulate mitochondrial function. Accordingly, various reagents used for regulating mitochondrial enzyme activities and promoting biogenesis have been documented, among which mitochondria-targeted cation, TPP-conjugated antioxidants are the most valuable for future trials and clinical treatment to improve mitochondrial function as they may take advantage of the prognosis associated with septic complications.
- 26 November 2018
- Published by Springer Nature in Military Medical Research
- Vol. 5 (1) , 1-11
Open AccessPotential therapy strategy: targeting mitochondrial dysfunction in sepsis
Recently, the definition of sepsis was concluded to be a life-threatening organ dysfunction caused by a dysregulated host response to infection. Severe patients always present with uncorrectable hypotension or hyperlactacidemia, which is defined as septic shock. The new definition emphasizes dysregulation of the host response and multiple organ dysfunction, which is partially attributed to metabolic disorders induced by energy crisis and oxidative stress. Mitochondria are a cellular organelle that are well known as the center of energy production, and mitochondrial damage or dysfunction is commonly induced in septic settings and is a predominant factor leading to a worse prognosis. In the present review, we determine the major mitochondrial disorders from morphology to functions in sepsis. In the following, several clinical or pre-clinical assays for monitoring mitochondrial function are demonstrated according to accumulated evidence, which is the first step of specific therapy targeting to modulate mitochondrial function. Accordingly, various reagents used for regulating mitochondrial enzyme activities and promoting biogenesis have been documented, among which mitochondria-targeted cation, TPP-conjugated antioxidants are the most valuable for future trials and clinical treatment to improve mitochondrial function as they may take advantage of the prognosis associated with septic complications.